论文部分内容阅读
目的:比较阿司匹林联合缓释型双嘧达莫和阿司匹林预防急性缺血性卒中后预防脑血管缺血事件的疗效。方法:60例发病48小时内急性缺血性卒患者随机分为联合组(n=30)和阿司匹林组(n=30),分别采用联合应用阿司匹林和缓释型双嘧达莫(50mg,2次/d;双嘧达莫100mg,2次/d)和单独应用阿司匹林(50mg,2次/d)进行抗血小板治疗。随访6个月,比较2组脑血管缺血事件发生率和NIHSS评分降低值,并记录药物不良反应。结果:治疗组3例失访和1例终止实验,对照组5例失访,进入结果分析的例数为51例。联合组的患者6个月内脑血管缺血事件发生率明显低于单独应用阿司匹林组(11.5%vs.20.0%,P<0.05)。而且,联合组NIHSS评分比单独应用阿司匹林降低更明显(4.52±1.8vs.3.62±3.3,P<0.05)。结论:联合应用阿司匹林和双嘧达莫在急性缺血性卒中后预防脑血管缺血事件的疗效明显优于单独应用阿司匹林。
OBJECTIVE: To compare the efficacy of aspirin combined with extended-release dipyridamole and aspirin in preventing cerebrovascular ischemia after acute ischemic stroke. Methods: Sixty patients with acute ischemic stroke within 48 hours after onset were randomly divided into combined group (n = 30) and aspirin group (n = 30). The patients were treated with combination aspirin and extended-release dipyridamole (50mg, 2 Day / d; dipyridamole 100 mg, twice daily) and aspirin alone (50 mg twice daily) for antiplatelet therapy. The patients were followed up for 6 months. The incidence of cerebrovascular ischemic events and the NIHSS score were compared between the two groups. The adverse drug reaction was recorded. Results: Three patients in the treatment group were lost to follow-up and one patient was terminated. Five patients in the control group were lost to follow-up. The number of cases entering the analysis was 51. The incidence of cerebrovascular ischemic events within 6 months in the combination group was significantly lower than that in the aspirin alone group (11.5% vs. 20.0%, P <0.05). Moreover, the NIHSS score in the combined group was significantly lower than aspirin alone (4.52 ± 1.8 vs. 3.62 ± 3.3, P <0.05). CONCLUSIONS: The combination of aspirin and dipyridamole in the prevention of cerebrovascular ischemia after acute ischemic stroke is significantly superior to aspirin alone.